Business Wire

Vector Capital to Acquire Showpad

26.8.2025 22:00:00 CEST | Business Wire | Press Release

Share

Vector Capital Management, L.P., a leading private equity firm specializing in transformational investments in established technology businesses, today announced an agreement to acquire Showpad, a leader in AI revenue enablement technology with headquarters in Chicago and Ghent, Belgium.

Customers in over 50 countries —including Coca-Cola, Dow, DuPont, GE Healthcare, Kaiser Permanente and Schneider Electric — leverage Showpad to bring together marketing and revenue teams to engage buyers and add value at every interaction. The company is a Forrester Wave™ leader in multiple categories2, and a “Customers’ Choice” for Revenue Enablement Platforms3 on Gartner® Peer Insights™.

After the transaction closes, Vector will combine Showpad with Bigtincan Holdings, which it acquired in April 2025. The combined entity will operate under the Showpad brand. It will deliver a complete AI-powered revenue enablement solution across all aspects of buyer-seller engagement with broad geographic diversity, and combined R&D resources to accelerate innovation market-wide.

Bigtincan is a five-time leader in The Aragon Research Globe™for Sales Enablement Platforms and has received multiple awards for AI and other innovations. Over 1,000 companies — including Abbott, AT&T, Clorox, Merck, Winnebago, and 100 of the Fortune 500 — use Bigtincan’s AI-powered sales enablement solutions to augment, automate and modernize seller and buyer engagement.

“The combination of Bigtincan with Showpad brings together best-in-class innovation and market leaders with thousands of customers,” said Amish Mehta, Chief Investment Officer and Managing Director at Vector Capital. “The combined company will lead the digital and AI-fueled buyer and seller engagement and drive a new generation of experiences that people and brands love.”

Insight Partners, a large investor in Showpad, will roll over its full investment into the combined company. The completion of the transaction is subject to customary conditions, including regulatory approval. Further terms were not disclosed, and the transaction is expected to close in 2025.

Watershed Moment in AI-Powered Revenue Enablement Market

“The merger of Showpad and Bigtincan represents a watershed moment for the sales enablement market,” said Jim Lundy, Founder and Lead Analyst at Aragon Research. “By uniting complementary strengths in content, readiness, and AI, the combined company is poised to deliver on the market's unmet demand for AI-centric sales enablement platforms that are easier to deploy, simpler to use and more impactful for revenue teams worldwide."

“Our unwavering focus on driving success for customers fueled a record-breaking year of growth for Showpad in 2024,” said Hendrik Isebaert, CEO of Showpad. “Together we will deliver a breadth of flexible solutions and an incredible team to help customers engage with buyers in new and creative ways they never thought possible.”

“Evolving preferences and rapid technology advancements are aggressively transforming buying and selling behaviors,” said Jim Hopkins, Chairman of Bigtincan. “We invested early and heavily in AI, and our combined global R&D resources will accelerate innovation so customers can rapidly reap the benefits of AI and emerging future innovations.”

Sidley Austin LLP is serving as legal counsel, Deloitte LLP is serving as tax advisor and Alvarez & Marsal is serving as financial advisor to Vector Capital. Cleary Gottlieb Steen & Hamilton LLP is acting as legal counsel and TD Securities is acting as financial advisor to Showpad.

“Vector Capital has a long history of building category-defining technology companies,” said Rob Amen, Managing Director at Vector Capital. “Both companies bring impressive industry expertise and commitment to excellence. Together, they will continue to drive the future and set industry standards and best practices globally.”

For more, visit our acquisition information page and follow Bigtincan, Showpad and Vector Capital on LinkedIn.

About Vector Capital Management, L.P.

Vector Capital is a leading San Francisco-based investment firm focused on transformational investments in middle-market technology and technology-enabled businesses. Founded in 1997, Vector manages over $4 billion of capital across credit and private equity strategies on behalf of a high-quality group of global limited partners. For nearly 28 years, Vector has combined technology investments with operational transformation to deliver breakthrough results. For more information, visit www.vectorcapital.com.

1 Grand View Research, Sales Enablement Platform Market Size Report, 2030.

2 Forrester Wave™: Revenue Enablement Platforms, Q3 2024, and Sales Readiness Solutions, Q4 2023 reports.

3 Gartner, Gartner Peer Insights 'Voice of the Customer': Revenue Enablement Platforms, Peer Contributors, April 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250826870353/en/

Contacts

Bryan Scanlon
Look Left Marketing
vector@lookleftmarketing.com
+1 (925) 759-3265

Vector Capital:
Nathaniel Garnick / Grace Cartwright
Gasthalter & Co.
+1 (212) 257-4170 - vector@gasthalter.com

Showpad:
Moon Kang
+2 (804) 601-0583
moon.kang@showpad.com

Bigtincan:
Denise Iverson
+1 (214) 509-8557
denise.iverson@bigtincan.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye